Cited by 162Protein Tyrosine PhosphatasesChronic Myeloid Leukemia TreatmentsProtein Kinase Regulation and GTPase Signaling

A Novel SH2-Containing Phosphatidylinositol 3,4,5-Trisphosphate 5-Phosphatase (SHIP2) Is Constitutively Tyrosine Phosphorylated and Associated With src Homologous and Collagen Gene (SHC) in Chronic Myelogenous Leukemia Progenitor Cells

Wisniewski, David, Strife, Annabel, Swendeman, Steve, Erdjument-Bromage, Hediye, Geromanos, Scott, Kavanaugh, W. Michael, Tempst, Paul, Clarkson, Bayard·1999·Blood

Abstract

Because of the probable causal relationship between constitutive p210bcr/abl protein tyrosine kinase activity and manifestations of chronic-phase chronic myelogenous leukemia (CML; myeloid expansion), a key goal is to identify relevant p210 substrates in primary chronic-phase CML hematopoietic progenitor cells. We describe here the purification and mass spectrometric identification of a 155-kD tyrosine phosphorylated protein associated with src homologous and collagen gene (SHC) from p210bcr/abl-expressing hematopoietic cells as SHIP2, a recently reported, unique SH2-domain–containing protein closely related to phosphatidylinositol polyphosphate 5-phosphatase SHIP. In addition to an N-terminal SH2 domain and a central catalytic region, SHIP2 (like SHIP1) possesses both potential PTB(NPXY) and SH3 domain (PXXP) binding motifs. Thus, two unique 5-ptases with striking structural homology are coexpressed in hematopoietic progenitor cells. Stimulation of human hematopoietic growth factor responsive cell lines with stem cell factor (SCF), interleukin-3 (IL-3), and granulocyte-macrophage colony-stimulating factor (GM-CSF) demonstrate the rapid tyrosine phosphorylation of SHIP2 and its resulting association with SHC. This finding suggests that SHIP2, like that reported for SHIP1 previously, is linked to downstream signaling events after activation of hematopoietic growth factor receptors. However, using antibodies specific to these two proteins, we demonstrate that, whereas SHIP1 and SHIP2 selectively hydrolyze PtdIns(3,4,5)P3 in vitro, only SHIP1 hydrolyzes soluble Ins(1,3,4,5)P4. Such an enzymatic difference raises the possibility that SHIP1 and SHIP2 may serve different functions. Preliminary binding studies using lysates from p210bcr/abl-expressing cells indicate that both Ptyr SHIP2 and Ptyr SHIP1 bind to the PTB domain of SHC but not to its SH2 domain. Interestingly, SHIP2 was found to selectively bind to the SH3 domain of ABL, whereas SHIP1 selectively binds to the SH3 domain of Src. Furthermore, in contrast to SHIP1, SHIP2 did not bind to either the N-terminal or C-terminal SH3 domains of GRB2. These observations suggest (1) that SHIP1 and SHIP2 may have a different hierarchy of binding SH3 containing proteins and therefore may modulate different signaling pathways and/or localize to different cellular compartments and (2) that they may be substrates for tyrosine phosphorylation by different tyrosine kinases. Because recent evidence has clearly implicated both PI(3,4,5)P3 and PI(3,4)P2 in growth factor-mediated signaling, our finding that both SHIP1 and SHIP2 are constitutively tyrosine phosphorylated in CML primary hematopoietic progenitor cells may thus have important implications in p210bcr/abl-mediated myeloid expansion.

Integrity signals

Registry

Crossref · 10.1182/blood.v93.8.2707

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 73 · Cited by 162

Authors
Wisniewski, D., Strife, A., Swendeman, S., Erdjument-Bromage, H., Geromanos, S., Kavanaugh, W. M., Tempst, P., & Clarkson, B.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • From the Sloan-Kettering Institute for Cancer Research, Molecular Pharmacology and Therapeutics Program and Molecular Biology Program, and Memorial Hospital for Cancer and Allied Diseases, Department of Medicine, Division of Hematologic Oncology, Leukemia Service, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY; the Chiron Corp, Emeryville, CA; and Cornell University Medical College, New York, NY.
Venue
Blood
Published
1999-04-15
Volume
93
Issue
8
Pages
2707-2720
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1774940923
Cited by
162
References
73
Citations by year
2024: 1 · 2023: 5 · 2022: 1 · 2019: 5 · 2018: 1 · 2017: 2 · 2016: 4 · 2015: 3 · 2014: 6 · 2013: 9 · 2012: 6
FWCI
4.25
Type
journal article
Language
en
Open access
closed
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (P01CA64593, P30-CA-08748, P01CA064593, P30CA008748)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
SHIP1, SH2 domain, Shc, chronic myeloid leukemia, p210 BCR-ABL, tyrosine phosphorylation, hematopoietic progenitor cells, SH3 domain, hematopoietic growth factor receptors
MeSH terms
Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases, Collagen, Hematopoietic Stem Cells, Humans, Phosphoric Monoester Hydrolases, Phosphoproteins, Phosphorylation, Tumor Cells, Cultured, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, src Homology Domains, Phosphotyrosine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review